Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis
- 281 Downloads
Viruses such as Epstein-Barr virus (EBV) which can establish latent infections in the central nervous system or the immune system have been associated with chronic neurological disorders, including multiple sclerosis. Results vary, therefore the aim of this study was to investigate the presence of EBV using both viral DNA and antibody screening techniques, using PCR and ELISA assays respectively, to evaluate viral presence in blood from control subjects and patients with multiple sclerosis. Viral gene sequences for latent proteins EBNA-1 and LMP-1 and lytic gene BamH1-W were present equally in both patients and controls (<7%). Anti-EBV-VCA IgG positive cases were present in >99% of all study subjects, and anti-EBV-VCA IgG immune status ratio showed a near-significant positive correlation with the EDSS in patients with multiple sclerosis. In contrast, Anti-EBV-VCA IgM positive cases were significantly increased in patients (controls: 23.3%; patients; 41.9%; P = 0.046). The IgM to IgG immune status ratio was near-significantly higher in patients with relapse episodes in the year preceding blood sampling (P = 0.058). Results from this and previous studies have shown higher prevalence rates for EBV evaluating anti-EBV IgM positive cases against viral DNA positive cases. Also, IgM, an innate immune response, showed an association with relapse episodes, suggesting viral re-activation as a contributing factor to these relapses.
KeywordsMultiple sclerosis Epstein-Barr virus Anti-EBV-VCA IgG Anti-EBV-VCA IgM Kurtzke extended disability status scale
We would like to extend our sincere gratitude to the MS Society, Western Cape Branch, South Africa and sister Treska Botha for the recruitment of patients.
This study was funded by a grant from the University Research Fund of the Cape Peninsula University of Technology, South Africa.
Conflict of interest
- Cinque P, Brytting M, Wahren B, Linde A, Cinqueb P, Castagna A, Lazzarin A, Vago L, Parravicini C, Zanchetta N, D’Arminio Monforte A (1993) Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 342:398–401PubMedCrossRefGoogle Scholar
- Hay KA, Tenser RB (2000) Leukotropic herpesvirus in multiple sclerosis. Mult Scler 5:66–68Google Scholar
- Lungu O, Gershon AA (2006) Latency and reactivation of VZV. In: Gross G, Doerr HW (eds) Herpes Zoster. Monogr Virol. Karger, Basel. pp. 9–12Google Scholar
- Myhr K-M, Riise T, Barrett-Conner E, Myrmel H, Vedeler C, Gronning M, Kalvenes MB, Nyland H (1998) Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psychiatry 64:539–542PubMedCrossRefGoogle Scholar
- Santiago O, Gutierrez J, Sorlozano A, De Dios LJ, Villegas E, Fernandez O (2010) Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-010-0940-0
- Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, Dillner J, Forsgren L (2004) An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology 62:2277–2282Google Scholar
- Vera-Sempere FJ, Burgos JS, Botella MS, Cordoba J, Gobernado M (1996) Immunohistochemical expression of Epstein-Barr virus encoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Oral Oncol Eur J Cancer 32B:163–168CrossRefGoogle Scholar